REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Reform agenda puts China's economic superagency under scrutiny

Mon, 15th Jul 2013 21:02

By Alexandra Harney

SHANGHAI, July 16 (Reuters) - Behind China's twoinvestigations into irregular pricing of infant formula andpharmaceuticals announced this month is one powerful institutionand its struggle for relevance as Beijing attempts a transitionto a more consumption-led economy.

The investigations have entangled big foreign companiesincluding Danone SA, Nestle SA andGlaxoSmithKline Plc. But some analysts say there may besomething deeper at work - jockeying over the direction ofpolicy in the world's second largest economy in the years ahead.

The National Development and Reform Commission (NDRC),Beijing's economic superagency, sets policy for strategicindustries, approves big investments, mergers and acquisitions,and has the authority to influence prices for everything fromliquor to gasoline.

Its powers are so sweeping that it is often called the"little State Council".

But in recent months, as President Xi Jinping and Premier LiKeqiang have begun an attempt to steer China's economy away fromits reliance on state-led investment towards a moreconsumer-focused model, academics and even senior officials havebegun to publicly cast doubt on the NDRC's role.

While the NDRC has always had a price-setting role, itsdecision to launch high profile predatory pricing probes intoinfant formula and drugs now could be a bid by the commission toprove its usefulness as a regulator.

"On a fundamental level, the NDRC is scrambling to show thatit has something to contribute," says Barry Naughton, professorat the University of California, San Diego, and a specialist inChina's economy.

SHIFTING PRIORITIES

That the main economic policy body in the fastest-growingmajor economy over the past decade might feel the need to shoreup its position says much about the debate raging among Chinesepolicymakers. In key areas, the new leaders are trying to shiftChina's priorities in ways that represent a challenge to theNDRC's traditional dominance.

Evidence that dominance could be under threat includes thefact that Premier Li made the reduction of bureaucraticapprovals - one of the NDRC's main roles - a key plank of hisreform plan announced in March.

In May, Li also rejected a 40 trillion yuan ($6.5 trillion)urbanisation plan that the NDRC had proposed, sources familiarwith the matter told Reuters, although the commission deniesthis.

Xi and Li remain committed to urbanisation, but the push nowis "less about building stuff", says Arthur Kroeber, managingdirector of GaveKal Dragonomics Research, and more about helpingmigrants live "more fully-fledged urban lives".

Reducing bureaucratic red tape - such as the NDRC approvalsprocess - is another way the new administration would like toshrink the role of the state in the economy.

There are also concerns among academics about the NDRC as aninstitution. Founded in 1952 as the State Planning Commission,it is deeply rooted in China's command economy past, even as itcrafts policies for its mostly capitalist present.

Part of the debate is about whether, through its investmentapproval function, the NDRC is allocating resources asefficiently as possible, says Shi Lei, professor of economics atFudan University. Overcapacity plagues many industries in China.

With so much power concentrated in one institution,corruption is another worry - Liu Tienan, former NDRC vicechairman, is under investigation over allegations he took bribesto help a businessman defraud banks.

REGULATORY ROLE

The NDRC is no stranger to controversy. It has facedchallenges to its power before and has found ways to survive andeven increase its influence.

Indeed, this month's drugs and formula investigations couldwell be a sign that the NDRC is adapting to the new mood inBeijing by strengthening its role as a regulator.

Especially since the 2011 introduction of regulationsgoverning its role in implementing the 2008 Anti-Monopoly Law,the NDRC has been stepping up its investigations into pricingpractices.

In March, it imposed a 449 million yuan fine on two domesticliquor firms for setting minimum resale prices and a 10 millionyuan fine on eight real estate companies for misleadingcustomers and violating pricing regulations.

In January, it found six foreign LCD manufacturers guilty ofprice fixing and fined them 353 million yuan.

Few sectors pack the symbolic punch of infant formula, bothfor Chinese consumers and the government. Since 2008, whenmelamine in infant formula killed six babies and sickened300,000 others, the infant formula industry has epitomized thetrade-off between rapid economic growth and health and safety.

Driving down prices also supports Beijing's efforts to shiftthe economy away from a reliance on exports and investmenttoward a greater dependence on consumption. Drugs and infantformula are both commonly perceived as too expensive.

"Every time price reductions are made, it's mainly a publicrelations exercise," said Zhou Zhang, an analyst at ChinaMerchant Securities. "The NDRC trumpets how big reductions willbe, but when it comes down to it, prices only fall a bit. TheNDRC's main consideration is public relations."

The NDRC did not respond to a request for comment. Oneperson with knowledge of the NDRC investigations said that theywere being conducted at an unusually rapid pace.

The infant formula investigation also appears to cover notcollusion among companies, but how the retail prices for theseproducts are set - an issue where China's laws differ from thosein other countries, including the United States.

All of the infant formula companies targeted have reducedprices in China since the NDRC announced its investigation.

That might be good for consumers in the short term, butScott Kennedy, director of the Research Center for ChinesePolitics & Business at Indiana University, questioned the NDRC'scredentials as a consumer watchdog, given its central role inChina's export- and investment-led expansion of the past twodecades.

"This is an economy built by, for and of industry," he said.

More News
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.